High Drug Prices Spur New Call to Probe Impact of IP Rights (1)

Republican Sen. Thom Tillis is upping a call for the Food and Drug Administration to investigate claims that pharmaceutical companies’ intellectual property rights are a culprit behind the high costs for blockbuster drugs.

The Biden administration, Democratic lawmakers and activists have all taken shots at the American IP system for fueling those costs. But many stakeholders are doubtful that patents are to blame, with some taking issue with data used to bolster such claims.

The ranking member of the Judiciary IP Subcommittee, Tillis said the information behind allegations of “dozens or hundreds of patents” blocking generic competition for biopharmaceutical ...